Pharmaceuticals news continually updated from thousands of sources around the net.
1 hr ago | Scoop
Bart Ellenbroek A Victoria University of Wellington researcher will discuss why pharmaceutical industry success rates are so low and suggest solutions to tackle this crisis at an inaugural professorial lecture next Tuesday. Professor Bart Ellenbroek, from the School of Psychology, will focus on why the pharmaceutical industry is less successful, in terms of new drug registrations when there has been increasing expenditure on research and development over the last few decades.
5 hrs ago | Star Tribune
Until May 1999, the daytime speed limit in Montana was "reasonable and prudent." Leadfoots from around the country called it the home of the Montanabahn.
6 hrs ago | Applied Clinical Trials
It is estimated that by the end of 2014, pharmaceutical companies will lose approximately $78 billion USD as a result of medications going off patent.1 Additionally, the industry is facing significant competition and a widening gap between proposed pricing for new medications and what reimbursement structures are willing to pay. To address some of these trends and in an effort to "do more with less," the pharmaceutical industry has been outsourcing not only its IT and back-office functions, but also parts of its core business for some years, and which led to the emergence and growth of the large contract research organization .
10 hrs ago | Business Journal
President Barack Obama's signature Affordable Care Act has spurred plenty of attacks on the pharmaceutical industry, but it has also created opportunities, according to Flagship Ventures partner Harry Wilcox. The recent launches of drugs with high up-front costs have revived the longstanding debate over how much new medicines ought to cost.
13 hrs ago | GlobeNewswire
The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of certain purchasers of shares of Impax Laboratories Inc over alleged Violations of Federal Securities Laws by Impax Laboratories Inc. If you purchased shares of Impax Laboratories Inc , you have certain options and for certain investors are short and strict deadlines running. Deadline: October 13, 2014.
14 hrs ago | Business Journal
Lannett Co. Inc. said Tuesday its outside review of the company's pricing practices for digoxin, a generic heart medicine, found the company acted in compliance with applicable laws and regulations.
16 hrs ago | Seeking Alpha
If Achillion's nucleotide , ACH-3422, works as well or worse than Gilead's Sovaldi, there is little use for it in the market. Since May, Achillion has experienced an avalanche of selling by insiders and major holders, and no reported buying by institutions.
Today McKesson Health Solutions announced that the Clear Coverage TM platform has been reappraised at Level 3 of the CMMI Institute's Capability Maturity Model Integration , a process improvement training and appraisal program administered by , Senior Vice President, CIO/CTO at McKesson Health Solutions. 'Attaining CMMI Level 3 reaffirms the Clear Coverage team's dedication to defined development processes that help reduce risk, sustain high quality and support continuous process improvement for our customers.'
This comprehensive SWOT profile of Kukje Pharmaceutical Industry Co., Ltd. provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats.
Raptor Pharmaceutical Corp. was down 6.1% during trading on Monday after an insider sold shares in the company, ARN reports. The stock traded as low as $10.26 and last traded at $10.46, with a volume of 230,583 shares.
Achillion Pharmaceuticals has received a consensus recommendation of "Buy" from the twelve analysts that are presently covering the company, ARN reports . One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company.
McKesson has received a "BBB+" credit rating from analysts at Morningstar . The firm's "BBB+" rating indicates that the company is a moderate default risk.
Mylan Inc. said it had licensed a Hepatitis C treatment for developing countries.
Southpointe-based Mylan said Mylan Laboratories Ltd. said its deal with Gilead includes non-exclusive rights for sofosbuvir, also known as Sovaldi, and a single-tablet regimen of ledipasvir/sofosbuvir in 91 countries that have 54 percent of the infected population of Hepatitis C. Mylan said it would be able to manufacture low-cost versions of the medicines, which were approved by the FDA in 2013 and 2014. "Hepatitis C is a growing public health problem in developing countries, with Central and East Asia and North Africa among the regions most affected by this disease.
Teva is trying to recover the Copaxone sales loss due to patent expiration by introducing an improved version of Copaxone 40mg. Teva revealed positive data from the phase 3 study of its drug reslizumab for the treatment of moderate to severe asthma.
Raptor Pharmaceutical Corp. Director Raymond Anderson sold 10,000 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $10.81, for a total transaction of $108,100.00.
The FDA grants tentative approval for Mylan's emtricitabine and tenofovir disoproxil fumarate combination tablets co-packaged with nevirapine tablets for the treatment of patients with HIV-1. The product is cleared for use alone or in combination with other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients at least 12 years old and weighing at least 38 kg.
Updated: Tue Sep 16, 2014 09:14 pm
Copyright © 2014 Topix LLC